The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan

Abstract Background The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protoco...

Full description

Bibliographic Details
Main Authors: Tao Chen, Susan Chan, Gideon Lack, Suzie Cro, Victoria R. Cornelius
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Trials
Subjects:
Statistical analysis plan
Eczema
Paediatric
Atopic dermatitis
Anti-IgE
Omalizumab
Online Access:http://link.springer.com/article/10.1186/s13063-017-1976-6

Internet

http://link.springer.com/article/10.1186/s13063-017-1976-6

Similar Items